Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Henlius' Herceptin Biosimilar Approved for European Use

publication date: Jul 30, 2020

Shanghai Henlius Biotech has been approved to market its Herceptin biosimilar to patients with HER2-positive cancers in Europe. Zercepac® is the first Henlius biosimilar to be approved for use in Europe. One year ago, the company was approved to market its Rituxan biosimilar in China to treat non-Hodgkin lymphoma, the first biosimilar approved in China. Henlius, a subsidiary of Fosun Pharma, partnered the biosimilar with Accord Pharma of the UK for European distribution. It is Accord's third approved biosimilar. More details....

Stock Symbols: (HK: 2696) (SHA: 600196; HK: 2196)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China